- The Washington Times - Friday, March 12, 2004

ASSOCIATED PRESS

The Senate approved Mark McClellan’s nomination early yesterday to head the government’s mammoth Medicare program, despite his rankling of many in Congress by opposing the importation of prescription drugs.

Senators confirmed President Bush’s choice by voice vote and no debate. At a Senate committee hearing Thursday, Mr. McClellan seemingly did little to satisfy lawmakers who want the administration to reverse itself and let Americans buy prescription drugs entering the country from Canada and elsewhere.

Sen. Byron L. Dorgan, North Dakota Democrat, who had delayed the nomination, said he decided to let it go after becoming convinced that Senate Majority Leader Bill Frist, Tennessee Republican, had the votes needed for approval.

Mr. Dorgan also said Mr. Frist had agreed to commit to a process that could eventually allow the importation of drugs. In an interview, Mr. Frist said he, Mr. Dorgan and other senators agreed to develop proposals for the safe importation of drugs, though no timetable was specified.

“We’re trying to move the ball forward here, to make progress” toward the use of imported drugs, Mr. Dorgan said in a brief interview.

Mr. Frist later issued a statement praising Mr. McClellan as “an extremely bright and capable public servant” who would be “providing strong leadership at this critical time.”

Mr. McClellan, who is commissioner of the Food and Drug Administration, has argued that lifting the ban could result in patients receiving unsafe drugs.

Drug importation has broad support in Congress and among the public. Anger about rising drug prices in the United States is outweighing concerns about the safety of drugs purchased abroad, especially over the Internet.

During debate last year on Medicare prescription drug legislation, Republican congressional leaders and the White House blocked inclusion of a plan that would have allowed drug imports. Mr. Bush signed legislation in December adding drug benefits to the huge health insurance program for the elderly and disabled.

At a Senate hearing, Mr. McClellan did not commit to supporting legalized importation of drugs. But he pledged to work with senators who are developing legislation to address safety issues, such as giving the FDA more money for drug inspections, that Mr. McClellan and other government officials have identified.

“We’re going to be working hard with help from the public to answer these questions about whether and how imported drugs would be safe,” he told members of the Senate Commerce, Science and Transportation Committee.

Mr. Dorgan said in response, “There’s no evidence you’ve been interested in that at all.”

Mr. Dorgan and the Senate committee chairman, Republican John McCain of Arizona, as well as other lawmakers had been upset with Mr. McClellan’s refusal to testify about imported drugs before his confirmation. Mr. McClellan agreed to testify Thursday, after Mr. Dorgan said he would block confirmation.

Senators quickly made their displeasure known. When Mr. McClellan did not, in Mr. McCain’s view, respond adequately to his first question, Mr. McCain said, “You come to this committee after having stiffed us, having stiffed the House of Representatives and my first question … you won’t answer.”

Nearly two hours later, Mr. McCain was advising the 40-year-old physician and economist that the administration would be politically wise to recognize the widespread support for importing drugs and giving Medicare the power to negotiate directly with pharmaceutical companies, which the new law expressly prohibits.

One indication of the shifting political winds came from Sen. Trent Lott, Mississippi Republican, who until now has backed the administration’s position.

“I cannot explain to my mother any longer why she should pay twice or two-thirds more than what is paid in Canada and Mexico,” Mr. Lott said, while also urging the Senate to confirm Mr. McClellan promptly.

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide